期刊文献+

贲门癌组织中syndecan-1表达及临床意义 被引量:1

原文传递
导出
摘要 目的探讨syndecan-1与贲门癌临床病理特征及预后的关系。方法采用免疫组织化学SP法检测癌旁正常贲门黏膜、癌旁不典型增生组织、贲门癌组织中syndecan-1表达情况,并分析syndecan-1与临床病理特征及预后的关系。结果 syndecan-1蛋白在贲门癌组织、不典型增生组织和癌旁正常组织中的表达率分别为38.9%(28/72)、76.9%(20/26)、100.0%(40/40);syndecan-1蛋白表达强度与贲门癌分化程度、浆膜浸润、淋巴结转移及预后呈负相关(P<0.05);syndecan-1表达阳性组与阴性组生存曲线差异有统计学意义(P<0.05)。结论 syndecan-1表达缺失与贲门癌发生、发展及预后密切相关。
出处 《中华实用诊断与治疗杂志》 2013年第12期1199-1200,共2页 Journal of Chinese Practical Diagnosis and Therapy
  • 相关文献

参考文献8

  • 1Teng Y H, Aquino R S, Park P W. Molecular functions of syndecan-1 in disease[J]. Matrix Biol,2012,31(1) :3-16.
  • 2Fux L, Ilan N, Sanderson R D, el al. Heparanase: busy at the cell surface[J]. Trends Biochem Sci,2009,34(10) :511- 519.
  • 3Conejo J R, Kleeff J, Koliopanos A, et al. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers[J]. Int J Cancer,2000,88(1):12- 20.
  • 4邹金,李亨芬,邢咏梅,聂金梅,白如玉,刁勇.不同抗原修复方法对Ki-67蛋白检测结果的影响[J].中华实用诊断与治疗杂志,2011,25(7):664-666. 被引量:5
  • 5曲智锋,徐远,王培,穆双锋,李敬霞.5-氟尿嘧啶同步化、放疗治疗局部晚期贲门癌32例临床观察[J].中华实用诊断与治疗杂志,2010,24(4):392-393. 被引量:2
  • 6茹艺,冯笑山,蔡向前,王公平,高社干,米建强,陈强,肖中岳.p57kip2在贲门癌中的表达及意义[J].中华实用诊断与治疗杂志,2011,25(10):984-985. 被引量:1
  • 7Juuti A, Nordling S, Lundin J, etal. Syndecan 1 expression: a novel prognostic marker in pancreatic cancer [J ]. Oncology, 2005,68(2/3) :97 -106.
  • 8Kim Y I, Lee A, Lee B H, et al. Prognostic signi{icance of syndecan-1 expression in cervical cancers[J]. J Gynecol Oncol, 2011,22(3) :161-167.

二级参考文献33

  • 1曹守强,邹小明,李福军,李晓林,张天华,秦华东,张建国.P57^(kip2)蛋白在进展期胃癌中的表达及临床意义[J].哈尔滨医科大学学报,2004,28(6):561-563. 被引量:4
  • 2张秀凤,王益民,李琰,郭炜,王娜,王瑞,魏丽珍,葛晖,曹延延,张健慧.CDH1基因3’非编码区单核苷酸多态性与食管癌、贲门癌的关系[J].实用诊断与治疗杂志,2007,21(4):241-244. 被引量:8
  • 3倪灿荣.病理学技术[M].北京:人民卫生出版社,2000:366-368.
  • 4殷蔚伯,余子豪,徐国镇,等.肿瘤放射治疗学[M].4版.北京:中国协和医科大学出版社,2007:809.
  • 5Balandraud P, Moutardier V, Giovannini M, et al. Locally advanced adenocarcinomas of the gastric cardia: results of preoperative chemoradiotherapy[J]. Gastroenterol Clin Biol,2004, 28(9):651-657.
  • 6Kurokawa Y, Sasako M. Recent advances in chemotherapy and chemoradiotherapy for gastrointestinal tract cancers: adjuvant chemoradiotherapy for gastric eancer[J]. Int J Clin Oncol,2008, 13(6):479-482.
  • 7Stahl M, Walz M K, Stuschke M, et al. Phase Ⅲ comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction[J]. J Clin Oncol,2009,27(6):851-856.
  • 8Willett C G, Czito B G. Chemoradiotherapy in gastrointestinal malignancies[J]. Clin Oncol (R Coll Radiol), 2009,21 (7): 543-556.
  • 9Kundel Y, Levitt M L, Oberman B, et al. Adjuvant chemotherapy and whole abdominal irradiation for gastric carcinoma[J]. Tumori,2008,94(4):469-473.
  • 10Jansen E P, Boot H, Saunders M P, et al. A phase Ⅰ-Ⅱ study of postoperative eapecitabine-based chemoradiotherapy in gastric cancer[J]. Int J Radiat Oncol Biol Phys, 2007,69(5):1424-1428.

共引文献5

同被引文献7

  • 1熊宏超,张力建,杨跃,梁震,吴楠,陈晋峰.123例贲门癌外科治疗的临床分析[J].癌症,2006,25(1):100-104. 被引量:22
  • 2周际昌.实用内科学.北京:人民卫生出版社.2003.591-592.
  • 3Gaspar LE,Nag S,Herskovic A,et al.American Brachytherapy Society (ABS) consensus guidelines for brachy therapy of esophageal cancer[J].Int Radiat Oncol Biol Pbys,1997,38:127-132.
  • 4Takubo K,Mafune K,Tanaka Y,et al.Pathology of the cardia[J].Ninon Geka Gekkai Zasshi,1998,99:547-552.
  • 5Vtyurin BM,Medvedev VS,Ivanov VN,et al.Perioperative neutron brachy therapy with californium-252[J].Int J Radiat Oncol Biol Phys,1992,23:873-879.
  • 6Maruyama Y,Mesina J,Yudelev M,et al,New understanding from Cf brachytherapy trials and considerations for neutron therapy of bulky gyn carcinoma for future[J].Strahlenther Onkol,1994,170:253-263.
  • 7董跃华,魏玉磊,王大伟,杨燕君,崔玉环.新辅助化疗对贲门癌患者Ki-67和VEGF蛋白表达与预后的影响[J].中国临床医生杂志,2014,42(3):44-46. 被引量:11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部